{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu GF"],"funding":["HSRD VA"],"pagination":["e18114"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10844707"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(3)"],"pubmed_abstract":["Patients with Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL-3-independent cell proliferation through activation of the p-PDGFRB and p-STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitivity to imatinib in vitro. When transfused into mice, Ba/F3 cells with the TERF2::PDGFRB fusion gene induce tumorigenesis and a shortened lifespan in cell-derived graft models, but this outcome can be improved with imatinib treatment. In summary, we have identified the novel TERF2::PDGFRB fusion gene, which exhibits oncogenic potential both in vitro and in vivo, making it a potential therapeutic target for tyrosine kinase inhibitors (TKIs)."],"journal":["Journal of cellular and molecular medicine"],"pubmed_title":["The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL."],"pmcid":["PMC10844707"],"funding_grant_id":["I01 HX000232"],"pubmed_authors":["Fu HH","Qiu HY","Li J","Zhou Q","Xie XQ","Wang B","Zeng Z","Zhang ZB","Xu GF","Xiao Q","Wang M","Liu Y","He S","Chen SN","Chen Y","Zhang XM","Shi J","Yang ZL"],"additional_accession":[]},"is_claimable":false,"name":"The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.","description":"Patients with Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL-3-independent cell proliferation through activation of the p-PDGFRB and p-STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitivity to imatinib in vitro. When transfused into mice, Ba/F3 cells with the TERF2::PDGFRB fusion gene induce tumorigenesis and a shortened lifespan in cell-derived graft models, but this outcome can be improved with imatinib treatment. In summary, we have identified the novel TERF2::PDGFRB fusion gene, which exhibits oncogenic potential both in vitro and in vivo, making it a potential therapeutic target for tyrosine kinase inhibitors (TKIs).","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-04T08:07:54.57Z","creation":"2025-04-04T08:07:54.57Z"},"accession":"S-EPMC10844707","cross_references":{"pubmed":["38323741"],"doi":["10.1111/jcmm.18114"]}}